Trends in Immunotherapy

Article

Mechanism and preclinical models of neuropathic pain: An update

Downloads

https://doi.org/10.54963/ti.v9i1.974
Melkani, I., Kumbhar, P., Parasher, P., Kumar, S., Himani, Kumar, B., & Mazumder, R. (2025). Mechanism and preclinical models of neuropathic pain: An update. Trends in Immunotherapy, 9(1), 23–44. https://doi.org/10.54963/ti.v9i1.974
Volume 9 Issue 1 (2025)
Copyright (c) 2025 Indu Melkani, Pankaj Parasher, Prashant Kumbhar, Shubham Kumar, Himani, Bimlesh Kumar, Rupa Mazumder
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

  • Indu Melkani School of Pharmaceutical Sciences, Lovely Professional University, Punjab 144411, India
  • Prashant Kumbhar School of Pharmaceutical Sciences, Lovely Professional University, Punjab 144411, India
  • Pankaj Parasher School of Pharmaceutical Sciences, Lovely Professional University, Punjab 144411, India
  • Shubham Kumar School of Pharmaceutical Sciences, Lovely Professional University, Punjab 144411, India
  • Himani School of Pharmaceutical Sciences, Lovely Professional University, Punjab 144411, India
  • Bimlesh Kumar
    School of Pharmaceutical Sciences, Lovely Professional University, Punjab 144411, India
  • Rupa Mazumder Department of Pharmaceutics Noida Institute of Engineering and Technology, Greater Noida, Uttar Pradesh 201308, India

Neuropathic pain is a debilitating condition that is a product of nervous system damage or dysfunction. Since the drugs prescribed by the physician provide partial pain relief to the patients. Hence, current updates for its treatment are required. It is a global concern as neuropathic pain happens in many diseased conditions like cancer, trauma, surgery and diabetics, etc. Developed as well as developing countries are both trying to find suitable medicine. Understanding the mechanisms behind it can be crucial for the effective treatment and management of neuropathic pain. Central sensitization in the spinal cord and brain amplifies pain signals, increasing pain sensitivity even without tissue damage. Peripheral sensitization, at the injury site, sensitizes peripheral nerves, lowering pain thresholds. Recognizing and studying these sensitizations are vital for understanding and managing chronic neuropathic pain and improving patients’ quality of life. The present manuscript encompasses a mechanism and model for neuropathic pain in animals with its advantages and disadvantages.

Keywords:

Peripheral Sensitization; Central Sensitization; Neuropathic Pain; Pain Signals

References

  1. Davis, M.D. Richardson, M.D.P., Davis, S.L.E., et al. Disorders of Pain and Headache. In: Fundamentals of Neurologic Disease. Springer: New York, NY, USA, 2015; pp. 245–257.
  2. Alles, S.R.A., Smith, P.A. Etiology and Pharmacology of Neuropathic Pain. Pharmacol. Rev. 2018, 70, 315–347. DOI: https://doi.org/10.1124/pr.117.014399
  3. Jaggi, A.S., Jain, V., Singh, N., et al. Animal Models of Neuropathic Pain. Fundam. Clin. Pharmacol. 2011, 25, 1–28.
  4. Woolf, C.J., Mannion, R.J. Neuropathic Pain: Aetiology, Symptoms, Mechanisms, and Management. Lancet 1999, 353, 1959–1964.
  5. Muthuraman, A., Singh, N., Jaggi, A.S., et al. Effect of Hydroalcoholic Extract of Acorus Calamus on Tibial and Sural Nerve Transection-Induced Painful Neuropathy in Rats. J. Natural Med. 2011, 65, 282–292. DOI: https://doi.org/10.1007/s11418-010-0486-6
  6. Cavalli, E., Mammana, S., Nicoletti, F., et al. The Neuropathic Pain: An Overview of the Current Treatment and Future Therapeutic Approaches. Int. J. Immunopathol. Pharmacol. 2019, 33. 2058738419838383.
  7. Baskozos, G., Fu, Y., Gray, D., et al. Epidemiology of Neuropathic Pain: An Analysis of Prevalence and Associated Factors in UK Biobank. Pain Rep. 2023, 8, e1066.
  8. Melkani, I., Kumar, S., Singh, P., et al. Neuropathic Pain and Diabetes: A Complicated Clinical Condition. AIP Conf. Proc. 2024, 2986, 1.
  9. Colloca, L., Ludman, T., Bouhassira, D., et al. Neuropathic Pain. Nat. Rev. Dis. Primers 2017, 3, 17002. DOI: https://doi.org/10.1038/nrdp.2017.2.Neuropathic
  10. Baron, R. Mechanisms of Disease: Neuropathic Pain - A Clinical Perspective. Nature Clin. Pract. Neurol. 2006, 2, 95–106. DOI: https://doi.org/10.1038/ncpneuro0113
  11. Baron, R., Binder, A., Wasner, G., et al. Neuropathic Pain: Diagnosis, Pathophysiological Mechanisms, and Treatment. Lancet Neurol. 2010, 9, 807–819. DOI: https://doi.org/10.1016/S1474-4422(10)70143-5
  12. Shyu, B.-C., Vogt, B.A., Short-Term Synaptic Plasticity in the Nociceptive Thalamic-Anterior Cingulate Pathway. Mol. Pain 2009, 5, 51.
  13. Dworkin, R.H., O’Connor, A.B., Backonja, M., et al. Recommendations for the Pharmacological Management of Neuropathic Pain: An Overview and Literature Update. Mayo Clin. Proc. 2010, 85, S3–S14. DOI: https://doi.org/10.4065/mcp.2009.0649
  14. Finnerup, N.B., Haroutounian, S., Kamerman, P., et al. Neuropathic Pain: An Updated Grading System for Research and Clinical Practice. Pain 2016, 157, 1599–1606. DOI: https://doi.org/10.1097/j.pain.0000000000000492
  15. Iyengar, S., Ossipov, M.H., Johnson, K.W., et al. The Role of Calcitonin Gene–Related Peptide in Peripheral and Central Pain Mechanisms Including Migraine. Pain 2017, 158, 543–559.
  16. Malhotra, R. Understanding Migraine: Potential Role of Neurogenic Inflammation. Ann. Indian Acad. Neurol. 2016, 19, 175–182.
  17. Barker, P.A., Mantyh, P., Arendt-Nielsen, L., et al. Nerve Growth Factor Signaling and Its Contribution to Pain. J. Pain Res. 2020, 13, 1223–1241.
  18. Weber, K.T., Schmaderer, M., Bock, K., et al. Serum Levels of the Proinflammatory Cytokine Interleukin-6 Vary Based on Diagnoses in Individuals with Lumbar Intervertebral Disc Diseases. Arthritis Res. Ther. 2016, 18, 1–14.
  19. Hu, M., Palić, D. Micro-and Nano-Plastics Activation of Oxidative and Inflammatory Adverse Outcome Pathways. Redox Biol. 2020, 37, 101620.
  20. Li, W., Li, J., Liu, S., et al. Peripheral and Central Pathological Mechanisms of Chronic Low Back Pain: A Narrative Review. J. Pain Res. 2021, 14, 1483–1494.
  21. D’Mello, R., Dickenson, A.H.. Spinal cord mechanisms of pain. Br. J. Anaesth. 2008, 101, 8–16.
  22. Barygin, O.I., Nagaeva, E.I., Tikhonov, D.B., et al. Inhibition of the NMDA and AMPA receptor channels by antidepressants and antipsychotics. Brain Res. 2017, 1660, 58–66. DOI: http://dx.doi.org/10.1016/j.brainres.2017.01.028
  23. Atas, U., Erin, N., Tazegul, G., et al. Changes in ghrelin, substance P and vasoactive intestinal peptide levels in the gastroduodenal mucosa of patients with morbid obesity. Neuropeptides 2021, 89, 102164.
  24. Fuchs, D., Birklein, F., Reeh, P.W., et al. Sensitized peripheral nociception in experimental diabetes of the rat. Pain 2010, 151, 496–505.
  25. Kowaluk, E.A., Arneric, S.P. Novel molecular approaches to analgesia. Ann. Rep. Med. Chem. 1998, 33, 11–20.
  26. Ashraf, S., Bouhana, K.S., Pheneger, J., et al. Selective inhibition of tropomyosin-receptor-kinase A (TrkA) reduces pain and joint damage in two rat models of inflammatory arthritis. Arthritis Res. Ther. 2016, 18, 97. DOI: https://doi.org/10.1186/s13075-016-0996-z
  27. Kinnman, E., Levine, J.D. Sensory and sympathetic contributions to nerve injury-induced sensory abnormalities in the rat. Neuroscience 1995, 64, 751–767.
  28. Kulkarni, S.K., Dhir, A. Possible involvement of l-arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the antidepressant activity of berberine chloride. Eur. J. Pharmacol. 2007, 569, 77–83.
  29. Muthuraman, A., Jaggi, A.S., Singh, N., et al. Ameliorative effects of amiloride and pralidoxime in chronic constriction injury and vincristine-induced painful neuropathy in rats. Eur. J. Pharmacol. 2008, 587, 104–111.
  30. Muthuraman, A., Ramesh, M., Sood, S. Development of animal model for vasculatic neuropathy: Induction by ischemic-reperfusion in the rat femoral artery. J. Neurosci. Methods 2010, 186, 215–221.
  31. Tarquini, R., Pala, L., Brancati, S., et al. Clinical approach to diabetic cardiomyopathy: a review of human studies. Curr. Med. Chem. 2018, 25, 1510–1524.
  32. Lai, J., Hunter, J.C., Porreca, F. The role of voltage-gated sodium channels in neuropathic pain. Curr. Opin. Neurobiol. 2003, 13, 291–297.
  33. Ueda, H. Peripheral mechanisms of neuropathic pain — involvement of lysophosphatidic acid receptor-mediated demyelination. Mol. Pain 2008, 4, 11. DOI: https://doi.org/10.1186/1744-8069-4-11
  34. Zakir, H.M., Mostafeezur, R.M., Suzuki, A., et al. Expression of TRPV1 channels after nerve injury provides an essential delivery tool for neuropathic pain attenuation. PLoS ONE 2012, 7, e44023.
  35. Nilius, B., Appendino, G., Owsianik, G. The transient receptor potential channel TRPA1: from gene to pathophysiology. Pflügers Arch. 2012, 464, 425–458.
  36. Wood, J.N. Molecular mechanisms of nociception and pain. Handb. Clin. Neurol. 2006, 81, 49–59. doi:10.1016/S0072-9752(06)80009-6.
  37. Cummins, T.R., Dib-Hajj, S.D., Waxman, S.G. Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy. J. Neurosci. 2004, 24, 8232–8236.
  38. Thakor, D.K., Lin, A., Matsuka, Y., et al. Increased peripheral nerve excitability and local Nav1.8 RNA up-regulation in painful neuropathy. Mol. Pain 2009, 5, 14.
  39. Lolignier, S., Bonnet, C., Gaudioso, C., et al. The Nav1.9 channel is a key determinant of cold pain sensation and cold allodynia. Cell Rep. 2015, 11, 1067–1078.
  40. Khanna, R., Yu, J., Yang, X., et al. Targeting the CaVα–CaVβ interaction yields an antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy. Pain 2019, 160, 1644.
  41. Cao, X., Byun, H., Chen, S., et al. Reduction in voltage-gated K+ channel activity in primary sensory neurons in painful diabetic neuropathy: role of brain-derived neurotrophic factor. J. Neurochemy. 2010, 114, 1460–1475.
  42. Tomita, S., Sekiguchi, F., Kasanami, Y., et al. Cav3.2 overexpression in L4 dorsal root ganglion neurons after L5 spinal nerve cutting involves Egr-1, USP5 and HMGB1 in rats: an emerging signaling pathway for neuropathic pain. Eur. J. Pharmacol. 2020, 888, 173587.
  43. Zhang, J., Rong, L., Shao, J., et al. Epigenetic restoration of voltage-gated potassium channel Kv1.2 alleviates nerve injury-induced neuropathic pain. J. Neurochem. 2021, 156, 367–378.
  44. Bennett, G.J., Xie, Y.-K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988, 33, 87–107. DOI: https://doi.org/10.1016/0304-3959(88)90209-6
  45. Melkani, I., Kumar, B., Panchal, S., et al. Comparison of sildenafil, fluoxetine and its co-administration against chronic constriction injury induced neuropathic pain in rats: an influential additive effect. Neurol. Res. 2019, 41, 875–882.
  46. Thakur, S., Srivastava, N. An update on neuropathic pain models. Int. J. Pharm. Pharm. Sci. 2016, 8, 11–16.
  47. Decosterd, I., Woolf, C.J. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 2000, 87, 149–158.
  48. Seltzer, Z., Dubner, R., Shir, Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 1990, 43, 205–218.
  49. Challa, S.R. Surgical animal models of neuropathic pain: pros and cons. Int. J. Neurosci. 2015, 125, 170–174.
  50. Hammarberg, H., Piehl, F., Risling, M., et al. Differential regulation of trophic factor receptor mRNAs in spinal motoneurons after sciatic nerve transection and ventral root avulsion in the rat. J. Comp. Neurol. 2000, 426, 587–601.
  51. Hsu, S.-T., Yao, C.-H., Hsu, Y.-M., et al. Effects of taxol on regeneration in a rat sciatic nerve transection model. Sci. Rep. 2017, 7, 42280.
  52. DeLeo, J.A., Coombs, D.W., Willenbring, S., et al. Characterization of a neuropathic pain model: sciatic cryoneurolysis in the rat. Pain 1994, 56, 9–16.
  53. Gheibi, S., Kashfi, K., Ghasemi, A. A practical guide for induction of type-2 diabetes in rat: incorporating a high-fat diet and streptozotocin. Biomed. Pharmacother. 2017, 95, 605–613.
  54. Kennedy, W.R., Quick, D.C., Miyoshi, T., Gerritsen, G.C.. Peripheral neurology of the diabetic Chinese hamster. Diabetologia 1982, 23, 445–51.
  55. Obrosova, I.G., Ilnytska, O., Lyzogubov, V.V., et al. High-fat diet-induced neuropathy of pre-diabetes and obesity: effects of “healthy” diet and aldose reductase inhibition. Diabetes 2007, 56, 2598–2608.
  56. Hasnie, F.S., Breuer, J., Parker, S., et al. Further characterization of a rat model of varicella zoster virus-associated pain: relationship between mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugs. Neuroscience 2007, 144, 1495–1508.
  57. Pan, H.-L., Khan, G.M., Alloway, K.D., et al. Resiniferatoxin induces paradoxical changes in thermal and mechanical sensitivities in rats: mechanism of action. J. Neurosci. 2003, 23, 2911–299.
  58. Miltenburg, N.C., Boogerd, W. Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat. Rev. 2014, 40, 872–882.
  59. Chopra, K., Tiwari, V. Alcoholic neuropathy: possible mechanisms and future treatment possibilities. Br. J. Clin. Pharmacol. 2012, 73, 348–362.
  60. Huang, W., Calvo, M., Pheby, T., et al. A rodent model of HIV protease inhibitor indinavir-induced peripheral neuropathy. Pain 2017, 158, 75–85.
  61. Abdeen, A., Samir, A., Elkomy, A., et al. The potential antioxidant bioactivity of date palm fruit against gentamicin-mediated hepato-renal injury in male albino rats. Biomed. Pharmacother. 2021, 143, 112154.
  62. Albin, R.L., Albers, J.W. Long-term follow-up of pyridoxine-induced acute sensory neuropathy-neuronopathy. Neurology 1990, 40, 1319.
  63. Nitta, A., Murai, R., Suzuki, N., et al. Diabetic neuropathies in brain are induced by deficiency of BDNF. Neurotoxicol. Teratol. 2002, 24, 695–701.
  64. Bennett, G.J. Pathophysiology and animal models of cancer-related painful peripheral neuropathy. Oncologist 2010, 15, 9–12.
  65. Xie, W.-R., Deng, H., Li, H., et al. Robust increase of cutaneous sensitivity, cytokine production and sympathetic sprouting in rats with localized inflammatory irritation of the spinal ganglia. Neuroscience 2006, 142, 809–822.
  66. Jimenez-Andrade, J.M., Herrera, M.B., Ghilardi, J.R., et al. Vascularization of the dorsal root ganglia and peripheral nerve of the mouse: implications for chemical-induced peripheral sensory neuropathies. Mol. Pain 2008, 4, 1744–8069.
  67. Krishnan, A.V., Kiernan, M.C. Uremic neuropathy: clinical features and new pathophysiological insights. Muscle Nerve 2007, 35, 273–290.
  68. Kumar, A., Kaur, H., Singh, A. Neuropathic pain models caused by damage to central or peripheral nervous system. Pharmacol. Rep. 2018, 70, 206–16.
  69. Tsuda, M. New approach for investigating neuropathic allodynia by optogenetics. Pain 2019, 160, S53–S58.
  70. Savastano, L.E., Laurito, S.R., Fitt, M.R., et al. Sciatic nerve injury: a simple and subtle model for investigating many aspects of nervous system damage and recovery. J. Neurosci. Methods 2014, 227, 166–180.
  71. Gabay, E., Tal, M. Pain behavior and nerve electrophysiology in the CCI model of neuropathic pain. Pain 2004, 110, 354–360.
  72. Andersen, M.L., Tufik, S. Sleep patterns over 21-day period in rats with chronic constriction of sciatic nerve. Brain Res. 2003, 984, 84–92.
  73. Hofmann, H.A., De Vry, J., Siegling, A., et al. Pharmacological sensitivity and gene expression analysis of the tibial nerve injury model of neuropathic pain. Eur. J. Pharmacol. 2003, 470, 17–25.
  74. Erichsen, H.K., Blackburn-Munro, G. Pharmacological characterisation of the spared nerve injury model of neuropathic pain. Pain 2002, 98, 151–161.
  75. Chung, A.W.Y., Yeung, K.A., Chum, E., et al. Diabetes modulates capacitative calcium entry and expression of transient receptor potential canonical channels in human saphenous vein. Eur. J. Pharmacol. 2009, 613, 114–118.
  76. Lindenlaub, T., Sommer, C. Partial sciatic nerve transection as a model of neuropathic pain: a qualitative and quantitative neuropathological study. Pain 2000, 89, 97–106.
  77. Rodrigues-Filho, R., Santos, A.R.S, Bertelli, J.A., et al. Avulsion injury of the rat brachial plexus triggers hyperalgesia and allodynia in the hindpaws: a new model for the study of neuropathic pain. Brain Res. 2003, 982, 186–194.
  78. Quintao, N.L.M, Balz, D., Santos, A.R.S, et al. Long-lasting neuropathic pain induced by brachial plexus injury in mice: role triggered by the pro-inflammatory cytokine, tumour necrosis factor α. Neuropharmacology 2006, 50, 614–620.
  79. Koka, R., Hadlock, T.A. Quantification of functional recovery following rat sciatic nerve transection. Exp. Neurol. 2001, 168, 192–195.
  80. Lee, S.E., Kim, J.-H. Involvement of substance P and calcitonin gene-related peptide in development and maintenance of neuropathic pain from spinal nerve injury model of rat. Neurosci. Res. 2007, 58, 245–249.
  81. Lindia, J.A., McGowan, E., Jochnowitz, N., et al. Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain. J. Pain. 2005, 6, 434–438.
  82. Willenbring, S., DeLeo, J.A., Coombs, D.W. Differential behavioral outcomes in the sciatic cryoneurolysis model of neuropathic pain in rats. Pain 1994, 58, 135–40.
  83. Dalziel, R.G., Bingham, S., Sutton, D., et al. Allodynia in rats infected with varicella zoster virus—a small animal model for post-herpetic neuralgia. Brain Res. Brain Res. Rev. 2004, 46, 234–242.
  84. Guedon, J.-M.G., Yee, M.B., Zhang, M., et al. Neuronal changes induced by varicella zoster virus in a rat model of postherpetic neuralgia. Virology 2015, 482, 167–180.
  85. Myers, M.G., Connelly, B.L. Animal models of varicella. J. Infect. Dis. 1992, 166, S48–S50.
  86. Salas, M.M., Clifford, J.L., Hayden, J.R., et al. Local resiniferatoxin induces long-lasting analgesia in a rat model of full-thickness thermal injury. Pain Med. 2017, 18, 2453–2465.
  87. Hsieh, Y.-L., Chiang, H., Tseng, T.-J., et al. Enhancement of cutaneous nerve regeneration by 4-methylcatechol in resiniferatoxin-induced neuropathy. J. Neuropathol. Exp. Neurol. 2008, 67, 93–104.
  88. Lin, C.-L., Chang, C.-H., Chang, Y.-S., et al. Treatment with methyl-β-cyclodextrin prevents mechanical allodynia in resiniferatoxin neuropathy in a mouse model. Biol. Open 2019, 8, bio039511.
  89. Sokolovska, J., Rumaks, J., Karajeva, N., et al. The influence of mildronate on peripheral neuropathy and some characteristics of glucose and lipid metabolism in a rat streptozotocin-induced diabetes mellitus model. Biomeditsinskaya Khimiya 2011, 57, 490–500.
  90. Akbarzadeh, A., Norouzian, D., Mehrabi, M.R., et al. Induction of diabetes by streptozotocin in rats. Indian J. Clin. Biochem. 2007, 22, 60–64.
  91. Ward, D.T., Yau, S.K., Mee, A.P., et al. Functional, molecular, and biochemical characterization of streptozotocin-induced diabetes. J. Am. Soc. Nephrol. 2001, 12, 779–90.
  92. Xu, Y., Jiang, Z., Chen, X. Mechanisms underlying paclitaxel-induced neuropathic pain: Channels, inflammation and immune regulations. Eur. J. Pharmacol. 2022, 933, 175288.
  93. Griffiths, L.A., Duggett, N.A., Pitcher, A.L., et al. Evoked and ongoing pain-like behaviors in a rat model of paclitaxel-induced peripheral neuropathy. Pain Res. Manag. 2018, 2018, 8217613.
  94. Duggett, N.A., Griffiths, L.A., McKenna, O.E., et al. Oxidative stress in the development, maintenance and resolution of paclitaxel-induced painful neuropathy. Neuroscience 2016, 333, 13–26.
  95. Julian, T., Glascow, N., Syeed, R., et al. Alcohol-related peripheral neuropathy: a systematic review and meta-analysis. J. Neurol. 2019, 266, 2907–2919.
  96. Tiwari, V., Kuhad, A., Chopra, K. Tocotrienol ameliorates behavioral and biochemical alterations in the rat model of alcoholic neuropathy. Pain 2009, 145, 129–136.
  97. Patil, S.R., Kumar, L., Kohli, G., et al. Validated, H.P.LC method for concurrent determination of antipyrine, carbamazepine, furosemide, and phenytoin and its application in assessment of drug permeability through Caco-2 cell monolayers. Sci. Pharm. 2012, 80, 89–100.
  98. Munawar, N., Oriowo, M.A., Masocha, W. Antihyperalgesic activities of endocannabinoids in a mouse model of antiretroviral-induced neuropathic pain. Front. Pharmacol. 2017, 8, 136.
  99. Joseph, E.K., Chen, X., Khasar, S.G., et al. Novel mechanism of enhanced nociception in a model of AIDS therapy-induced painful peripheral neuropathy in the rat. Pain 2004, 107, 147–158.
  100. Spooner, G.R., Desai, H.B., Angel, J.F., et al. Using pyridoxine to treat carpal tunnel syndrome: randomized control trial. Can. Fam. Physician. 1993, 39, 2122.
  101. Wang, Z.-B., Gan, Q., Rupert, R.L., et al. Thiamine, pyridoxine, cyanocobalamin, and their combination inhibit thermal, but not mechanical hyperalgesia in rats with primary sensory neuron injury. Pain. 2005, 114, 266–277.
  102. Hasannejad, F., Ansar, M.M., Rostampour, M., et al. Improvement of pyridoxine-induced peripheral neuropathy by Cichorium intybus hydroalcoholic extract through the GABAergic system. J. Physiol. Sci. 2019, 69, 465–476.
  103. Sullivan, K.A., Hayes, J.M., Wiggin, T.D., et al. Mouse models of diabetic neuropathy. Neurobiol. Dis. 2007, 28, 276–285.
  104. Wuarin-Bierman, L., Zahnd, G.R., Kaufmann, F., et al. Hyperalgesia in spontaneous and experimental animal models of diabetic neuropathy. Diabetologia 1987, 30, 653–658.
  105. Bolzán, A.D., Bianchi, M.S. Genotoxicity of streptozotocin. Mutat. Res./Rev. Mutat. Res. 2002, 512, 121–134.
  106. Islam, M.S. Animal models of diabetic neuropathy: progress since the 1960s. J. Diabetes Res. 2013, 2013, 149452.
  107. Shaikh, A.S., Somani, R.S.. Animal models and biomarkers of neuropathy in diabetic rodents. Indian J. Pharmacol. 2010, 42, 129–134.
  108. Deeds, M.C., Anderson, J.M., Armstrong, A.S., et al. Single-dose streptozotocin-induced diabetes: considerations for study design in islet transplantation models. Lab. Anim. 2011, 45, 131–40.
  109. Jimenez-Andrade, J.M., Mantyh, W.G., Bloom, A.P., et al. Bone cancer pain. Ann. N. Y. Acad. Sci. 2010, 1198, 173–81.
  110. Zhou, Y.-Q., Liu, Z., Liu, H.-Q., et al. Targeting glia for bone cancer pain. Expert Opin. Ther. Tar. 2016, 20, 1365–1374.
  111. Parker, R., Stein, D.J., Jelsma, J. Pain in people living with HIV/AIDS: a systematic review. J. Int. AIDS Soc. 2014, 17, 18719.
  112. Pardo, C.A., McArthur, J.C., Griffin, J.W. HIV neuropathy: insights into the pathology of HIV peripheral nerve disease. J. Peripher. Nerv. Syst. 2001, 6, 21–27.
  113. Wallace, V.C.J., Blackbeard, J., Segerdahl, A.R., et al. Characterization of rodent models of HIV-gp120 and antiretroviral-associated neuropathic pain. Brain 2007, 130, 2688–2702.
  114. Jefferys, J.G.R., Brismar, T. Analysis of peripheral nerve function in streptozotocin diabetic rats. J. Neurol. Sci. 1980, 48, 435–444.
  115. Tegnèr, R., Brismar, T. Experimental uremic neuropathy: Part 1. Decreased nerve conduction velocity in rats. J. Neurol. Sci. 1984, 65, 29–36.
  116. Chattopadhyay, M., Zhou, Z., Hao, S., et al. Reduction of voltage-gated sodium channel protein in DRG by vector-mediated miRNA reduces pain in rats with painful diabetic neuropathy. Mol. Pain 2012, 8, 17.
  117. Song, X.-S., Huang, Z.-J., Song, X.-J. Thiamine suppresses thermal hyperalgesia, inhibits hyperexcitability, and lessens alterations of sodium currents in injured dorsal root ganglion neurons in rats. Anesthesiology. 2009, 110, 387–400.
  118. Sterling, M., Davis, K.D. Introduction to the biennial review of pain. Pain 2024, 165, S1–S2.
  119. Sills, G.J. The mechanisms of action of gabapentin and pregabalin. Curr. Opin. Pharmacol. 2006, 6, 108–113.
  120. Kawano, T., Zoga, V., Kimura, M., et al. Nitric oxide activates ATP-sensitive potassium channels in mammalian sensory neurons: action by direct S-nitrosylation. Mol. Pain 2009, 5, 12.
  121. Li, Y., Zhang, L., Wu, Y., et al. Cannabinoids-induced peripheral analgesia depends on activation of BK channels. Brain Res. 2019, 1711, 23–28.
  122. Liu, C.-Y., Lu, Z.-Y., Li, N., et al. The role of large-conductance, calcium-activated potassium channels in a rat model of trigeminal neuropathic pain. Cephalalgia 2015, 35, 16–35.
  123. Deuis, J.R., Lim, Y.L., Rodrigues de Sousa, S., et al. Analgesic effects of clinically used compounds in novel mouse models of polyneuropathy induced by oxaliplatin and cisplatin. Neuro-Oncology 2014, 16, 1324–1332.
  124. Sandner, P., Stasch, J.P. Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence. Respir. Med. 2017, 122, S1–S9.
  125. Santos-Nogueira, E., Redondo Castro, E., Mancuso, R., et al. Randall-Selitto test: a new approach for the detection of neuropathic pain after spinal cord injury. J. Neurotrauma 2012, 29, 898–904.
  126. Sahoo, S.K., Panda, S. Raphanus sativus Linn. a new antinociceptive for diabetic neuropathy in rats determined by Randall-Selitto approach. Asian J. Pharm. Clin. Res. 2019, 12, 529–534.
  127. Jaggi, A.S., Singh, N. Differential effect of spironolactone in chronic constriction injury and vincristine-induced neuropathic pain in rats. Eur. J. Pharmacol. 2010, 648, 102–109.
  128. Irwin, S., Bennett, D.R., Hendershot, L.C., et al. The effects of morphine, methadone and meperidine on some reflex responses of spinal animals to nociceptive stimulation. J. Pharmacol. Exp. Ther. 1951, 101, 132–143.
  129. D’Amour, F.E., Smith, D.L. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 1941, 72, 74–79.
  130. Espejo, E.F., Mir, D. Structure of the rat’s behaviour in the hot plate test. Behav. Brain Res. 1993, 56, 171–176.
  131. Hargreaves, K., Dubner, R., Brown, F., et al. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988, 32, 77–81.
  132. Cheah, M., Fawcett, J.W., Andrews, M.R.. Assessment of thermal pain sensation in rats and mice using the Hargreaves test. Bio-protocol 2017, 7, e2506.
  133. Colburn, R.W., Lubin, M.L., Stone, D.J., et al. Attenuated cold sensitivity in TRPM8 null mice. Neuron 2007, 54, 379–386.
  134. Yamamoto, K., Tsuboi, M., Kambe, T., et al. Oxaliplatin administration increases expression of the voltage-dependent calcium channel α2δ-1 subunit in the rat spinal cord. J. Pharmacol. Sci. 2016, 130, 117–122.
  135. Hara, K., Haranishi, Y., Terada, T. Intrathecally administered perampanel alleviates neuropathic and inflammatory pain in rats. Eur. J. Pharmacol. 2020, 872, 172949.
  136. Deuis, J.R., Dvorakova, L.S., Vetter, I. Methods used to evaluate pain behaviors in rodents. Front. Mol. Neurosci. 2017, 10, 284.
  137. Bennett, G.J. What is spontaneous pain and who has it? J. Pain 2012, 13, 921–929.
  138. Wibbenmeyer, L., Sevier, A., Liao, J., et al. Evaluation of the usefulness of two established pain assessment tools in a burn population. J. Burn Care Res. 2011, 32, 52–60.
  139. Sotocina, S.G., Sorge, R.E., Zaloum, A., et al. The Rat Grimace Scale: a partially automated method for quantifying pain in the laboratory rat via facial expressions. Mol. Pain 2011, 7, 55.
  140. Jirkof, P., Cesarovic, N., Rettich, A., et al. Burrowing behavior as an indicator of post-laparotomy. Front. Behav. Neurosci. 2010, 4, 165.